Activist hedge fund Starboard Value's chief executive officer said on Tuesday that drugmaker Pfizer's board needs to hold ...

Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker ...

Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at ...

The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract ...

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

Activist investor Starboard met with Pfizer last week. Here's what went down, according to the hedge fund's cofounder and CEO ...

The company has made it easier to test for different protein modifications which are critical to the treatment of autoimmune ...

Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job.

Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people ...

Pfizer's focus should remain on existing cost realignment plans and pipeline investments. Read why my investment thesis ...

Pfizer’s Abrysvo is the first respiratory syncytial virus vaccine that can be used for adults less than 50 years of age.

Starboard Value criticizes Pfizer's leadership for underperformance, citing a 50% stock decline and missed growth targets ...